Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3.

Abacavir pharmacogenetics--from initial reports to standard of care.

Author information

1
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.

Abstract

Abacavir is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus infection as part of a multidrug, highly active antiretroviral therapy regimen. Despite its efficacy, approximately 5% of individuals who receive abacavir develop an immune-mediated hypersensitivity reaction (HSR) that warrants immediate discontinuation of abacavir and switching to an alternative antiretroviral regimen. Abacavir HSR is associated with individuals who carry the *57:01 variant in the human leukocyte antigen B (HLA-B) gene. There is a large volume of evidence to show that those who carry HLA-B*57:01 are at significantly increased risk of developing HSR and should not receive abacavir. Pharmacogenetic screening to ensure individuals who carry HLA-B*57:01 do not receive abacavir can reduce the incidence of HSR and is now considered the standard of care before prescribing abacavir. Genetic testing to prevent abacavir HSR is currently one of the best examples of integrating pharmacogenetic testing into clinical practice.

KEYWORDS:

AIDS; HIV; HLA; abacavir; drug hypersensitivity; genetic testing; pharmacogenetics

PMID:
23649914
PMCID:
PMC3700656
DOI:
10.1002/phar.1278
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center